Pregnant people schedule point

Data on this page show the responses of pregnant individuals who received the pregnant people pertussis (whooping cough) schedule point vaccine and completed an AusVaxSafety survey sent in the days following vaccination. Data on this page will be updated quarterly.

AusVaxSafety pregnant people schedule point influenza vaccine safety data are captured and reported throughout AusVaxSafety seasonal influenza vaccine safety surveillance. 

These data provide a profile of what to expect in the days following your pregnant people schedule point vaccinations and can assist in planning for vaccination. 

AusVaxSafety's active vaccine safety surveillance system complements the safety surveillance activities of the Therapeutic Goods Administration.

AusVaxSafety has been conducting safety surveillance of all National Immunisation Program (NIP) vaccines since 2019. Analysis has remained constant over this time and no safety concerns have been identified.

In April 2022, the vaccine safety survey used for active surveillance of vaccines on the NIP was updated to replicate the vaccine safety survey used for COVID-19 and seasonal influenza vaccine surveillance to allow for better comparison across all vaccines monitored. Data displayed on this page show analysis of the new survey. Reassuringly, data from the new vaccine safety survey are comparable to the rates reported in the previous survey. 

Further information on NIP vaccines can be found at the links below:

• National Immunisation Program schedule – Australian Government Department of Health and Aged Care
• AusVaxSafety Annual Summary Report – AusVaxSafety
• Pregnancy and newborn vaccinations – Sharing Knowledge About Immunisation (SKAI)
• Australian Immunisation Handbook – Australian Government Department of Health and Aged Care